China NMPA Drug Inspection - Shanghai Huayuan Pharmaceutical (Ningxia) Shasai Pharmaceutical Co., Ltd. - Thymopentin for Injection
China NMPA drug inspection for Shanghai Huayuan Pharmaceutical (Ningxia) Shasai Pharmaceutical Co., Ltd. published January 22, 2020. Drug: Thymopentin for Injection. The Ningxia Drug Administration issued an announcement on January 22, 2020, detailing drug sampling inspection results f
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Shanghai Huayuan Pharmaceutical (Ningxia) Shasai Pharmaceutical Co., Ltd. published January 22, 2020. Drug: Thymopentin for Injection. The Ningxia Drug Administration issued an announcement on January 22, 2020, detailing drug sampling inspection results f
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox